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ABBREVIATIONS
AHDS Allan-Herndon-Dudley syndrome
BHC Benign hereditary chorea
MCT8 Monocarboxylate transporter 8
Normal thyroid metabolism is essential for human development, including the formation and
functioning of the central and peripheral nervous system. Disorders of thyroid metabolism
are increasingly recognized within the spectrum of paediatric neurological disorders. Both
hypothyroid and hyperthyroid disease states (resulting from genetic and acquired aetiologies)
can lead to characteristic neurological syndromes, with cognitive delay, extrapyramidal
movement disorders, neuropsychiatric symptoms, and neuromuscular manifestations. In this
review, the neurological manifestations of genetic disorders of thyroid metabolism are out-
lined, with particular focus on Allan-Herndon-Dudley syndrome and benign hereditary chorea.
We report in detail the clinical features, major neurological and neuropsychiatric manifesta-
tions, molecular genetic findings, disease mechanisms, and therapeutic strategies for these
emerging genetic ‘brain-thyroid’ disorders.
The thyroid gland plays a fundamental role in normal
human development and maintenance, and it is therefore
not surprising that genetic and acquired disorders of thy-
roid metabolism often include prominent neurological dys-
function (Table I). The classical example of congenital
hypothyroidism (or ‘cretinism’1) clearly demonstrates this
association between abnormal thyroid function and neuro-
logical deficits. Affected infants are at substantial risk of
neurocognitive difficulties if L-thyroxine treatment is
delayed, whereas prompt institution of treatment usually
results in normal intellectual development.2 Other neuro-
logical features seen in congenital and later onset hypothy-
roidism include anxiety, depression, carpal tunnel
syndrome, peripheral neuropathy, headache, visual field
defects, and coma. At the other end of the spectrum,
patients with hyperthyroidism have been reported to have
an even wider range of neurological symptoms, including
anxiety, depression, psychosis, encephalopathy, marked tre-
mor, Graves ophthalmopathy, muscle weakness, and even
cerebrovascular events.3,4 Less frequently, deterioration in
cognitive function (affecting memory, attention, and plan-
ning), headaches, seizures, myasthenia, dysphonia, paroxys-
mal dyskinesias, and chorea5,6 have been found in
association with hyperthyroid states.
The pathophysiological processes underpinning the neu-
rological symptoms in hypothyroid and hyperthyroid states
are likely to be multifactorial, and include (1) autoimmune
mechanisms, for example in Hashimoto encephalopathy
(thyroid peroxidase, thyroglobulin, or thyroid microsomal
thyroid autoantibodies, association with autoimmune vascu-
litis), Graves disease (thyroid-stimulating hormone receptor
antibodies), and thyroid dysfunction related to myasthenia
gravis; (2) ‘channelopathy’ as seen in thyrotoxic periodic
paralysis; (3) adrenergic hypersensitivity associated with
hyperthyroid tremor; and (4) ischaemia in vascular strokes in
patients with hyperthyroid and atrial fibrillation.4 However,
the primary processes governing many neurological features
(e.g. cognitive dysfunction and psychiatric symptoms) in
abnormal thyroid states are not yet fully elucidated, and are
likely to be complex as a consequence of both the primary
and secondary effects of thyroid dysfunction on metabolic
cellular processes and neuronal networks.
The neurological spectrum associated with hypothyroid
and hyperthyroid states has rarely been systematically
reviewed in the literature,4 particularly with regard to
childhood manifestations. In addition to inborn errors of
thyroid metabolism and acquired thyroid disorders, more
recently, distinct genetic entities affecting normal forma-
tion and function of both brain and thyroid have been rec-
ognized. Although often associated with a wider range of
neurological manifestations, movement disorder pheno-
types feature prominently in these conditions. This is par-
ticularly interesting given the association of chorea and
dyskinesia with hyperthyroid states, suggesting a euthyroid
state may have a role in normal control of movement. In
this review we focus on the clinical features, molecular
genetic findings, pathophysiological disease mechanisms,
and therapeutic strategies for this emerging group of
genetic ‘brain-thyroid’ disorders.
ALLAN-HERNDON-DUDLEY SYNDROME
In 1944, William Allan, Nash Herndon, and Florence
Dudley reported a large North American pedigree
spanning six generations with 24 affected males character-
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ized by a distinct combination of dysmorphic features,
intellectual disability, and associated neurological findings.7
Further familial male cases with similar clinical features
and additional characteristic thyroid hormone abnormali-
ties were subsequently reported,8–14 resulting in the recog-
nition of Allan-Herndon-Dudley syndrome (AHDS;
OMIM 300523) as a distinct X-linked intellectual disability
syndrome. The subsequent identification of mutations in
the SLC16A2 gene encoding the monocarboxylate trans-
porter 8 (MCT8)9,15 established AHDS as the first geneti-
cally resolved neurodevelopmental disorder due to
defective thyroid hormone metabolism.
Disease onset
Presentation is typically from birth or early infancy.
Suggestive thyroid abnormalities are usually detectable
early in life, whereas dysmorphic features and in particular
neurological symptoms evolve over time.
Neurological/neuropsychiatric features
Neurological features associated with AHDS are variable
but evolve along a predictable trajectory throughout devel-
opment, with profound hypotonia prominent in early
infancy and gradual evolution of a spastic paraplegia
throughout childhood.10 Profound learning difficulties and
global developmental delay are common and most affected
children cannot walk or talk. A recognizable, particularly
placid and sociable personality trait has been suggested. A
dysmorphic mainly myopathic facial appearance (Fig. 1),
muscle wasting, contractures, pectus excavatum, and a scoli-
osis are often associated. There may be an associated rota-
tory nystagmus and dysconjugate eye movements.9 A
complex movement disorder usually evolves over time16,17
and may comprise dystonic posturing and choreoathetosis.
Paroxysmal dyskinesias, occurring spontaneously or trig-
gered by external stimuli such as sudden positional changes,
are a peculiar and often particularly distressing feature17,18
that may be difficult to distinguish from ‘seizures’ reported
to be present in a few individuals.19
Systemic disease features
General features associated with AHDS10,20 are variable,
but often include a dysmorphic, elongated facial appear-
ance with ptosis, bitemporal narrowing and simplified ears
Table I: Aetiology, and biochemical and clinical features of hypothyroidism, hyperthyroidism, Allan-Herndon-Dudley syndrome, and benign hereditary c-
horea
Hypothyroidism Hyperthyroidism AHDS BHC
Aetiology
Multiple aetiologies including: Grave’s Disease (GD) X-linked Mutation
in SLC16A2
Autosomal dominant
Mutation in NKX2.1Congenital hypothyroidism
Pituitary failure (PF)
Autoimmune thyroiditis (AT)
Hashimoto’s encephalopathy (HE)
Myxoedema coma
Biochemical features
TSH ↑ (↓in PF) ↓ N/mild ↑ ↑
Free T4 (thyroxine) ↓ ↑ N/mild ↓ ↓
Free T3 (triiodothyronine) ↓ ↑ ↑↑ (↓reverse T3) ↓
Antibodies (Ab) Thyroid peroxidase, thyroglobulin,
thyroid microsomal Ab (AT, HE)
TSH receptor
stimulating Ab (GD)
 
Neurological features
Chorea  ++ ++ +++
Dystonia  + ++ ++
Paroxysmal dyskinesia  + ++ +
Cognitive impairment ++ (congenital subgroup) + +++ +
Depression ++ ++  +
Anxiety ++ +++  
Seizures  + + 
Hypotonia ++ (congenital subgroup)  ++ ++
Muscle weakness ++ ++ ++ ++
Myasthenia gravis + +  
Periodic paralysis  +  
Carpal tunnel + +  
Tremor  +++ + +
Cerebellar ataxia +  + +
Peripheral neuropathy + +  
Stroke + +  
Headache + +  
Dysphonia + +  
AHDS, Allan-Herndon-Dudley syndrome; AT, autoimmune thyroiditis; BHC, benign hereditary chorea; GD, Graves disease; HE, Hashimoto
encephalopathy; N, normal; PF, pituitary failure; T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating hormone; (), Clinical Feature
not usually reported; (+), Clinical Feature sometimes reported; (++), Clinical Feature commonly reported; (+++), Clinical Feature reported in
most cases.
What this paper adds
• An overview of the neurological manifestations of thyroid dysfunction.
• Detailed characterization of the genetic ‘brain-thyroid’ disorders.
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(Fig. 1), and a head circumference at the lower end of the
normal range (0.4–9th centile). The diagnosis may be eas-
ily missed, as evidenced by a substantial proportion of
adults with genetically unexplained intellectual disability in
whom SLC16A2 mutations were retrospectively identi-
fied.21 Many affected males may have tachycardia and diffi-
culties gaining weight, reflecting a degree of peripheral
hyperthyroidism in tissues where thyroid hormone trans-
port is not MCT8-dependent.
Differential diagnosis
Particularly in cases where dysmorphic facial features are
not suggestive, a syndromic diagnosis of AHDS is often not
immediately suspected. The differential diagnosis evolves
with the typical clinical features over time, and may include
primary neuromuscular conditions, dystonic/dyskinetic
forms of cerebral palsy, and other causes of X-linked intel-
lectual disability. Of note, absent or reduced myelination in
the context of an evolving spastic paraplegia in males with
AHDS may lead to the misdiagnosis of Pelizaeus-Merzb-
acher disease,17,22 a disorder of myelination due to muta-
tions in the PLP1 gene on Xq22. SLC16A2 mutation
screening has therefore to be considered in males presenting
with features of Pelizaeus-Merzbacher disease or X-linked
spastic paraplegia,23 an allelic condition, once PLP1 muta-
tions have been excluded.
Laboratory findings
A specific combination of thyroid hormone abnormalities
reflective of increased renal thyroxine to triiodothyronine
conversion and altered thyroid gland hormone secre-
tion15,20,22,24 is the most distinctive laboratory marker of
AHDS and should prompt SLC16A2 sequencing in males
with other indicative features. Thyroid hormone abnormali-
ties suggestive of AHDS include normal or slightly elevated
serum thyroid-stimulating hormone levels, normal or mildly
decreased free thyroxine levels and, in particular, high free
or total triiodothyronine levels with a reduced reverse high
serum triiodothyronine concentration;25 as free, reverse,
and total triiodothyronine are not always part of the routine
laboratory thyroid assessment, the tests will have to be
specifically requested if there is a high clinical suspicion of
AHDS.26 A distinct thyroid follicular pathology has been
reported in mtm/ knockout mice and ought to be antici-
pated in patients with AHDS.27 Thyroid function should be
monitored in heterozygous female mutation carriers during
pregnancy, as deterioration of thyroid function may occur
and adversely affect even genetically unaffected fetuses.28
Other less specific laboratory abnormalities include
increased serum lactate concentrations, probably reflective
of a hyperthyroid metabolic myopathy,29 and increased
serum sex hormone-binding globulin concentrations, prob-
ably reflecting a thyroid hormone effect on the liver.
Increased ferritin and decreased cholesterol levels have
been observed in some individuals.30
Neuroimaging
A number of brain magnetic resonance imaging (MRI)
studies have indicated abnormal white matter development
in AHDS,17,20,22,31 supported by complementary magnetic
resonance spectroscopy findings in selected cases.17,32
Where studied longitudinally, brain MRI in patients with
AHDS shows absent or markedly reduced myelin at base-
line that develops slowly over time17,22 but remains sub-
stantially delayed on follow-up. The brain MRI appearance
is similar to that of Pelizaeus-Merzbacher disease.17,22
However, in contrast to PLP1-related Pelizaeus-Merzbach-
er disease, myelination appears to complete, eventually, in
older AHDS patients.
Other inconsistent MRI abnormalities reported in some
individuals with AHDS include subtle cortical, subcorti-
cal25 and cerebellar atrophy,33 as well as high T2 signal in
the putamina.34,35
Treatment
Movement disorder
Drugs usually given in the management of dystonic or
choreoathetoid movement disorders may also be consid-
(a) (b) (c)
Figure 1: A 4-year-old patient with genetically confirmed Allan-Herndon-Dudley syndrome, with photographs illustrating (a) face/trunk/limbs (b) facial
features and (c) lateral facial view. Note the typical but subtle dysmorphic features, including myopathic facial appearance with inverted V-shaped
mouth, low anterior hairline, narrow forehead, receding chin, and large, low-set ears. From Gika et al.,17 with permission.
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ered, but their efficacy has not been systematically evalu-
ated in patients with AHDS.
Thyroid dysfunction
Although thyroid hormone replacement may cause
improvement or normalization of laboratory markers, no
convincing effect on the neurological phenotype has been
observed.36,37
As the psychomotor retardation is thought to be caused
by impaired neuronal triiodothyronine uptake during brain
development, pharmacological efforts have concentrated on
triiodothyronine analogues that do not require MCT8 for
neuronal uptake.24 A recent pilot study with diiodothyro-
propionic acid,30 a thyroid hormone analogue that does
not rely on MCT8 for tissue entry, resulted in normaliza-
tion of laboratory thyroid parameters and reversed signs of
peripheral hyperthyroidism but did not improve neurologi-
cal features. The recent finding that the thyroid hormone
analogue 3,5,30,50-tetraiodothyroacetic acid (tetraiodothyro-
acetic acid or tetrac) stimulates thyroid hormone neuronal
differentiation in mct8/ mice suggests a novel pharmaco-
logical agent that may be of potential therapeutic benefit
in patients with AHDS.38
Molecular genetics and gene function
Causative mutations in the SLC16A2 (solute carrier family
16, member 2) gene on Xq13.8 have now been identified
in more than 170 males from 90 families and some hetero-
zygote carrriers,39,40 and probably also accounts for a pro-
portion of adult males with unresolved X-linked
intellectual disability.21 SLC16A2 belongs to the 14 mem-
bers of the SLC16 family of genes41 and encodes the
MCT8 protein. The majority of SLC16A2 mutations
results in complete loss of function, although few muta-
tions with clinically milder phenotypes may show residual
transporter activity. Known pathogenic SLC16A2 missense
mutations localize exclusively to the transmembrane helices
within the MCT8 protein.42
MCT8 is an active and specific thyroid hormone trans-
porter with differential tissue expression.43–46 In humans,
MCT8 shows preferential substrate specificity for triiodo-
thyronine and is early and widely expressed in the brain
(where its function appears most critical) and other tissues
including the heart, liver, kidneys, and skeletal muscle.24,45
In vitro studies have demonstrated that SLC16A2 muta-
tions result in a reduced or absent supply of triiodothyro-
nine to neurons47 and that genotype-phenotype
correlations largely reflect the residual triiodothyronine
transport capacity of the mutant MCT8 transporter on the
neuronal level,48 corresponding to the crucial role of thy-
roid hormones in brain development.46,49,50 More specifi-
cally, triiodothyronine induces differentiation of the
oligodendrocyte precursor, acts as a survival factor for oli-
godendrocytes51 and affects the distribution of myelin pro-
teins at later stages of oligodendroglial development.52
Although patients harbouring SLC16A2 mutations very
rarely exhibit signs of clinically overt hyperthyroidism,29
additional non-neurological symptoms are likely to reflect
a relative hyperthyroid state in tissues that are not
exclusively dependent on MCT8-mediated thyroid hor-
mone uptake (e.g. the liver25 and muscle33).
Two animal models of MCT8 deficiency have been gen-
erated recently, the mct8/ mouse53 and a transgenic ze-
brafish.54 The mct8/ mouse accurately replicates the
human thyroid profile,55,56 but does not show any of the
neurological features seen in patients with AHDS, suggest-
ing the presence of additional thyroid hormone transport-
ers with a synergistic effect in the mouse brain. However,
a recently generated transgenic zebrafish shows abnormali-
ties of neuronal development in the brain and spinal
cord,54 suggesting MCT8 as a crucial regulator during
embryonic neuronal development.
BENIGN HEREDITARY CHOREA (BRAIN-LUNG-
THYROID DISEASE)
First reported in 1967,57 benign hereditary chorea (BHC,
OMIM 118700) is an autosomal dominant, childhood
onset movement disorder characterized by non-progressive
chorea. It is a rare disorder and approximately 30 disease-
causing mutations have been reported in the literature to
date.58 Over time, it has been recognized that in some
patients, the neurological features are part of a multisystem
disorder, where affected patients have additional thyroid
and respiratory disease manifestations (brain-lung-thyroid
syndrome or choreoathetosis, hypothyroidism, and neona-
tal respiratory distress, OMIM 610978). Isolated BHC and
brain-lung thyroid syndrome are both caused by mutations
in the thyroid transcription factor gene, NKX2.1.
Disease onset
Benign hereditary chorea classically presents in childhood
(median age 3y) and it rarely presents after adolescence.59
The majority of affected children have a history of delay in
attaining early neurodevelopmental motor milestones58,60
and often present with delayed walking or with a ‘clumsy’
or ‘ataxic’ gait.58
Neurological/neuropsychiatric features
Chorea is the predominant movement phenotype and is
classically generalized, affecting the trunk and limbs. Spe-
cific triggers include premenstruation and pregnancy.58
The amplitude and severity of choreiform movements vary
greatly in patients with a good long-term prognosis. In
published series it appears that by early adulthood, the
chorea seems to either stabilize or resolve58 Other extrapy-
ramidal features, including limb/axial dystonia,61 ‘jerky’
dystonia,62 and myoclonus are also observed and can
further contribute to delayed motor development and
disability. Intention tremor,57 dysarthria,61 and gait distur-
bance62,63 are also reported. Comorbid psychiatric symp-
toms of depression,64 psychosis,65 motor vocal tics,58 and
attention-deficit–hyperactivity disorder58 have also been
reported in patients with BHC. In addition, a recent case
series reported a single patient with adolescent onset
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obsessive-compulsive disorder.60 Cognitive dysfunction is
also reported in patients with BHC58 and educational
support may be needed for many children with BHC. Rea-
sons for poor school performances are likely to be multi-
factorial58 and may include factors such as (1) the
movement disorder affecting writing ability; (2) psychiatric
comorbidities such as attention deficit hyperactivity disor-
der; (3) delayed treatment of hypothyroidism; and (4) peri-
natal hypoxic-ischaemic injury from respiratory distress.
Systemic disease features
It has been reported that approximately 30 to 50% of all cases
with NKX2.1mutations have the full triad of brain, lung, and
thyroid involvement.60 Hypothyroidism is commonly
reported in as many as two-thirds of patients with BHC.58 It
manifests as either congenital hypothyroidism (elevated thy-
roid-stimulating hormone, low thyroxine) presenting in the
neonatal period or as compensated hypothyroidism (elevated
thyroid-stimulating hormone, normal thyroxine) detected
later in childhood or even adulthood.58 Respiratory symp-
toms are less frequently reported (approximately half of BHC
cases) and can include neonatal respiratory distress syndrome
(alveolar syndrome due to surfactant deficiency), recurrent
chest infections, asthma, and lung cancer.58 Additional clini-
cal characteristics have been described in a number of cases
with NKX2.1 mutations. These include short stature with
growth hormone deficiency59,60 webbed neck,65 microceph-
aly, facial dysmorphia,59 hypodontia,66 visual impairment,60
patent foramen ovale,67 and malabsorption,59 as well as pes
cavus, kyphosis, duplex kidney, and lichen sclerosis. There is
much variability between BHC cases, both with regards to
the thyroid/lung involvement and the presence of other sys-
temic features, and the reasons for this are currently not
entirely clear. It is possible that the clinical phenotype may be
influenced by the nature of the NKX2.1 mutation, or that
some patients with contiguous gene deletions may have addi-
tional clinical features attributed to other genes also involved
in the copy number variant encompassing NKX2.1. In addi-
tion, other currently undetermined genetic and environmen-
tal factors may also play a role. As more genetically proven
cases of BHC are reported in the literature, the phenotypic
spectrum of the disease will become increasingly clear.
Differential diagnosis
The combination of early onset gait abnormalities, chorea,
and brain/lung involvement should trigger NKX2.1 testing,
but clinical diagnosis can be difficult in many cases. In the
early stages of the disease, non-specific gait abnormalities
may be similar to those seen in ‘dyskinetic’ or ‘ataxic’ cere-
bral palsy, as well as in acquired postinfectious and autoim-
mune chorea. Distinguishing BHC from DYT11-
myoclonus-dystonia syndrome (due to mutations in the
SGCE gene) can also be difficult.60 Asmus et al.62
attempted to identify clinical criteria differentiating BHC
from genetically proven myoclonus-dystonia and concluded
that early onset hypotonia, chorea in infancy, and possible
association with thyroid or lung disease were good
clues for differentiating BHC from this similar genetic
movement disorder. In addition, neuropsychiatric disorders
such as obsessive-compulsive disorder are much more com-
monly described in patients with DYT11-myoclonus-dysto-
nia syndrome than TITF1-BHC.
Laboratory findings
Patients with BHC may have thyroid function abnormalities
detected on laboratory testing, including low thyroxine and
high thyroid-stimulating hormone. As hypothyroidism is so
readily treated with L-thyroxine, patients presenting with
early onset chorea as well as other movement disorders and
neurodevelopmental delay should have thyroid function tests
as part of the initial diagnostic work-up. In addition, it is rec-
ommended that patients with mutation-positive BHC should
have regular thyroid function tests to (1) monitor disease and
thyroxine therapy in those with congenital hypothyroidism;
and (2) monitor for the evolution of later onset thyroid dis-
ease in patients with BHC without congenital hypothyroid-
ism, thereby allowing instigation of thryoxine replacement
therapy in a timely manner.58
Neuroimaging
Although neuroimaging studies have been normal in many
patients with BHC,60 isolated structural abnormalities have
been reported in a number of mutation-positive cases.
These include microcephaly and persistent cavum septum
pellucidum,68 agenesis of the corpus callosum,59 dience-
phalic cystic masses, and abnormal sella turcica.69 Volu-
metric analysis has shown a bilateral decrease in striatal
volume.70 Abnormalities on functional imaging in patients
with BHC have included hypometabolism of the basal gan-
glia and cortex with 18-fluoro-2-deoxy-glucose positron
emission tomography71 and reduced striatal and thalamic
uptake of technetium-99m-ethylcysteinate dimer.72
Treatment
Movement disorder
Although the symptoms of chorea have been targeted with
a wide variety of therapeutic strategies, the majority have
proven to be largely ineffective. Previous studies have
reported symptomatic improvement with (high-dose) levo-
dopa.73,74 Gras et al.58 reported the beneficial effect of
low-dose tetrabenazine (0.5mg/kg/d for children and
37.5mg/d in adults) for chorea and motor function that
was sustained at mean follow-up of 1.5 years. Improvement
of chorea with ropinirole treatment and partial response to
propranolol has also been reported in a single case.75
Hypothyroidism
L-Thyroxine replacement therapy is advocated, with regu-
lar monitoring of thyroid function tests.
Respiratory symptoms
Symptomatic treatment is recommended with antibiotics
for pulmonary infections and appropriate treatment for
symptoms of asthma (e.g. bronchodilators and steroids).
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Molecular genetics and gene function
Linkage analysis76 and positional cloning identified
NKX2.1 as the causative gene77 for BHC and brain-lung-
thyroid syndrome. NKX2.1 (also known as TITF1, TTF-1,
TEBP, or NXK2A) is located on chromosome 14q13.
NKX2.1 is a member of the NK gene family of highly con-
served homeodomain-containing transcription factors, spe-
cifically encoding thyroid transcription factor 1 protein,
which plays an important role in basal ganglia, thyroid,
and lung organogenesis.78 To date, more than 30 different
NKX2.1 mutations have been identified,58 mainly de novo
(two-thirds of cases) or inherited in an autosomal dominant
fashion (one-third of cases)58 with reduced penetrance.
Reported variants in BHC include whole gene deletions, as
well as splice-site, frameshift, nonsense, and missense
mutations. The majority of pathogenic mutations are pos-
tulated to either cause nonsense-mediated decay or cause
truncation of the resultant protein before or within the
DNA-binding homeobox domain (encoded by exon 3).
Thus, loss-of-function NKX2.1 mutations result in haploin-
sufficiency, and the resultant mutant protein has altered
DNA-binding properties and is thereby unable to activate
target genes.79 Murine models of disease were developed
by Kimura et al.80 They found that the T/ebp/ homozy-
gous state conferred lethality and that homozygotes
were born dead, with a rudimentary bronchial tree, abnor-
mal epithelium in their pleural cavities and absent lung
parenchyma, no thyroid/pituitary gland, and extensive
brain abnormalities, especially in the ventral forebrain.
Furthermore, Sussel et al.81 have demonstrated that murine
knockout homozygotes display abnormal neuronal migra-
tion from the pallidum to the striatum with subsequent
depletion of both cholinergic and GABAergic neurons, fur-
ther confirming the essential role of this gene in organo-
genesis of the thyroid, lung, and the central nervous
system, in particular ventral forebrain and pituitary gland.
CONCLUSION
Normal thyroid hormone metabolism is essential for the
physiological function of a wide range of organ systems,
including the brain. Inherited disorders affecting both nor-
mal brain and thyroid development and function (AHDS
and BHC, the ‘brain-thyroid’ disorders) are rare but
important to recognize, as they may mimic a wide range of
neurological and neuropsychiatric presentations, including
congenital neuromuscular disorders, cerebral palsy, pri-
mary movement disorders, certain leukodystrophies, and
(X-linked) intellectual disability. Moreover, although none
of these conditions can presently be cured, supportive
interventions are available that may alleviate disease mani-
festations. More rational therapeutic approaches are cur-
rently still at the experimental stage but may benefit
patients in the future.
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